

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE**

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 28 October 2016, 14 May 2017, 6 June 2017, and 19 September 2017 (the “**Previous Announcements**”) in relation to the research and development results of chimeric antigen receptor T (“**CAR-T**”) cell technology in immunotherapy for cancer cure by Nanjing Legend Biotechnology Co., Ltd.* 南京傳奇生物科技股份有限公司 (“**Nanjing Legend**”), a subsidiary of the Company as of the date of this announcement.

The Company is pleased to announce that, on 11 December 2017, the application for investigational new drug by Nanjing Legend (the “**Application**”) was accepted by the China Food and Drug Administration* (國家食品藥品監督管理總局) (the “**CFDA**”). Subject to the approval by the CFDA, Nanjing Legend shall be eligible to commence clinical trial of its proprietary CAR-T cell technology to treat multiple myeloma in the People’s Republic of China.

Please refer to the Previous Announcements of the Company for a brief introduction of the growth opportunities of Nanjing Legend from the treatment of multiple myeloma, CAR-T cell therapy, and the proprietary CAR-T cell technology. The Company believes that the acceptance of the Application by the CFDA indicates a positive sign in the further development and application of CAR-T cell therapy.

The Company wishes to note that the acceptance of the Application by the CFDA is only the first step towards the application for new drug in the People's Republic of China with respect to CAR-T cell technology. It is uncertain whether the CFDA will grant approval subsequent to its acceptance of the Application.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 11 December 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*